For example, from the results of the mt‐HBT (including MDMs, AFP, and sex) in clinical validation, its early‐stage sensitivity was 83% at 84% specificity in men, while the sensitivity was lower at 77% with a higher specificity at 91% in women.[13] Early detection of HCC is equally critical regardless of age or sex, however, the variation in model performance across different ages and sexes may pose challenges in meeting the clinical needs of younger females. This evidence concerns the gene AFP and hepatocellular carcinoma.